作者
Shilpa Grover, Michael Dougan, Kevin Tyan, Anita Giobbie‐Hurder, Steven M Blum, Jeffrey Ishizuka, Taha Qazi, Rawad Elias, Kruti B Vora, Alex B Ruan, William Martin‐Doyle, Michael Manos, Lauren Eastman, Meredith Davis, Maria Gargano, Rizwan Haq, Elizabeth I Buchbinder, Ryan J Sullivan, Patrick A Ott, F Stephen Hodi, Osama E Rahma
发表日期
2020/8/15
期刊
Cancer
卷号
126
期号
16
页码范围
3758-3767
简介
Background
There is a lack of predictive markers informing on the risk of colitis in patients treated with immune checkpoint inhibitors (ICIs). The aim of this study was to identify potential factors associated with development of ICI colitis.
Methods
We performed a retrospective analysis of melanoma patients at Dana‐Farber Cancer Institute who received PD‐1, CTLA‐4, or combination ICIs between May 2011 to October 2017. Clinical and laboratory characteristics associated with pathologically confirmed ICI colitis were evaluated using multivariable logistic regression analyses. External confirmation was performed on an independent cohort from Massachusetts General Hospital.
Results
The discovery cohort included 213 patients of whom 37 developed ICI colitis (17%). Vitamin D use was recorded in 66/213 patients (31%) before starting ICIs. In multivariable regression analysis, vitamin D use conferred significantly …
学术搜索中的文章
S Grover, M Dougan, K Tyan, A Giobbie‐Hurder… - Cancer, 2020